Ligand Pharmaceuticals (LGND) M&A announcement summary

Deal rationale and strategic fit

• Acquisition expands the royalty portfolio to over 200 assets, including seven commercial royalties and more than 100 development-stage programs, nearly doubling Phase 2 and 3 assets.

• Diversifies portfolio across development stages, therapeutic areas, and modalities, enhancing long-term growth and reducing reliance on single assets.

• Strengthens position as a leading biopharma royalty aggregator, supporting broader patient access and creating operating and financial synergies.

• Complements existing business model with a footprint in earlier-stage assets and aligns with ongoing investment strategy.

• Leverages XOMA's portfolio inflection point and robust pipeline for sustained growth.

Financial terms and conditions

• Purchase price is $39 per share in cash, totaling approximately $739 million, representing a 14% premium to XOMA's 30-day VWAP.

• Includes a non-transferable CVR per share, entitling holders to 75% of net proceeds from specific pending litigation.

• Funded through a mix of cash on hand and existing credit facility; Series X Convertible Preferred Stock to be converted, Series A and B Preferred Stock to be redeemed.

• All XOMA shares to be acquired in a one-step merger, subject to shareholder and regulatory approval, with closing targeted for Q3 2026.

• Entities holding 44% of XOMA shares have agreed to support the transaction.

Synergies and expected cost savings

• Immediate accretion to earnings, with $0.50 increase in adjusted EPS in 2026 and $1.50 in 2027.

• Adjusted core EPS guidance increased to $8.50–$9.50 for 2026; royalty revenue guidance raised to $225–$250 million, total revenue to $270–$310 million.

• Operating expenses rise modestly, but synergies and operating leverage drive a 10% increase in cash operating profit (~$20 million).

• Significant cost synergies expected through elimination of duplicative public company costs.

• Financial synergies and improved access to capital and business development opportunities.